3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
14
Neoplasm Metastasis
5
Rectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Pancreatic Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric Adenocarcinoma
1
Digestive System Diseases
1
Cholangiocarcinoma
1
Carcinoma
1
Bile Duct Neoplasms
1
Advanced or Metastatic Solid Tumors
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
Gemcitabine
153
Fluorouracil
45
Capecitabine
45
130-nm albumin-bound paclitaxel
43
Oxaliplatin
42
Albumin-Bound Paclitaxel
39
Leucovorin
31
Erlotinib Hydrochloride
30
pembrolizumab
23
Radiotherapy
22
Irinotecan
22
Radiosurgery
20
Bevacizumab
19
Docetaxel
17
Cyclophosphamide
17
Taxes
13
Cisplatin
13
Cetuximab
13
folfirinox
12
Nivolumab
11
Surgical Procedures, Operative
7
Paclitaxel
7
Ipilimumab
7
dehydroftorafur
6
Standard of Care
6
Radiation
6
Magnetic Resonance Spectroscopy
6
spartalizumab
5
ruxolitinib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pancreatic Neoplasms
×
trifluridine tipiracil drug combination
×
Clear all
NCT02921737
2021-02-04
UF-STO-PANC-003
University of Florida
Phase 2
Terminated
7 enrolled
12 charts